PregnancyNCT07054177
Metabolic Profiling of Saliva in Pregnancy and Periodontal Disease
An observational study of Pregnancy and Gingivitis and Periodontal Diseases, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).
Trial summary
This study aims to better understand how pregnancy affects the health of the gums and tissues that support the teeth. During pregnancy, hormone levels (like estrogen and progesterone) increase significantly. These hormonal changes can cause many changes in the body, including in the mouth. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pregnancy, Gingivitis and Periodontal Diseases
- How many people
- 30 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 24 Jun 2025to Apr 2026
- How long will I take part?
- 9 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: The study population includes systemically healthy pregnant women in different trimesters and postpartum period, and non-pregnant healthy women aged 18-40 years attending routine gynecology or periodontology clinics.
Who may be able to join
- Age between 18 and 40 years
- No history of systemic disease or chronic infection
- No use of antibiotics or anti-inflammatory drugs in the last 3 months
- Non-smoker and non-alcohol user
- Willingness to participate by signing the informed consent form
- Additional Criteria for Pregnant Volunteers:
Show all 13Show fewer
- Singleton pregnancy (no multiple gestation)
- Pregnancy progressing without complications (e.g., no diagnosis of preeclampsia, gestational diabetes, or threatened preterm labor)
- Gestational age confirmed by ultrasound
- Additional Criteria for Non-Pregnant Control Group:
- No history of pregnancy in the past 6 months
- Regular menstrual cycles
- No history of hormonal disorders (e.g., polycystic ovary syndrome, thyroid dysfunction)
Who cannot join
- Use of anti-inflammatory or antimicrobial treatments in the past 3 months
- Smoking or alcohol consumption
- Body mass index (BMI) > 30 kg/m²
- Presence of systemic diseases including diabetes mellitus, hyperprolactinemia, congenital adrenal hyperplasia, androgen-secreting tumors, thyroid dysfunction, Cushing's syndrome, hypertension, liver or kidney dysfunction
- Use of medications that may affect metabolic or hormonal parameters, such as oral contraceptives, steroid hormones, antihypertensives, or insulin-sensitizing drugs
- Periodontal treatment in the past 6 months
- Use of medications known to affect periodontal status (e.g., phenytoin, calcium channel blockers, cyclosporine, warfarin, NSAIDs, aspirin > 81 mg)
- Active infectious diseases such as hepatitis, HIV, or tuberculosis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Bezmialem Vakıf University, Faculty of Dentistry and Faculty of Medicine, Istanbul
Istanbul, Fatih, 34093
About this study
Official title: Salivary Metabolomics of Pregnancy and Periodontal Disease Related Metabolic Pathways
This study aims to better understand how pregnancy affects the health of the gums and tissues that support the teeth. During pregnancy, hormone levels (like estrogen and progesterone) increase significantly. These hormonal changes can cause many changes in the body, including in the mouth. Some pregnant women may notice that their gums become swollen, red, or bleed more easily - this is called pregnancy gingivitis. It happens more often during the second and third trimesters and usually improves after birth. Even if a pregnant person has good oral hygiene, hormonal changes may still make the gums more sensitive to plaque and bacteria. Scientists believe that these changes in gum health are linked to how the body responds to hormones, bacteria in the mouth, and changes in the immune system. To explore this further, saliva samples will be collected from:
- Pregnant women during their 1st, 2nd, and 3rd trimesters
- The same women again 6-8 weeks after giving birth
- A group of non-pregnant, healthy women as a comparison group The investigators will use a scientific method called untargeted metabolomics to study these saliva samples. This method helps looking at small substances (called metabolites) in saliva to see if there are any patterns related to pregnancy and gum health.
The goal is to identify biological changes that happen during pregnancy and understand how they might affect the gums. This research will help improve early detection and prevention of gum problems during pregnancy in the future.
Read the detailed description
The main objective of this study is to investigate the impact of physiological hormonal changes during pregnancy on periodontal status and to determine the metabolic pathways through which this effect occurs. For this purpose, saliva samples collected at different stages of pregnancy (1st, 2nd, and 3rd trimesters), in the postpartum period, and from systemically healthy non-pregnant individuals will be analyzed using an untargeted metabolomic approach based on LC-MS/MS. The analysis aims to identify potential metabolites and biochemical pathways that reflect the relationship between pregnancy-associated hormonal changes and periodontal tissues, thereby contributing to a better understanding of the underlying biological mechanisms.
This study will include 15 volunteer pregnant women aged 18-40, who are systemically healthy and whose pregnancy is progressing without complications, followed by a single gynecologist at the Department of Obstetrics and Gynecology, Bezmialem Vakıf University. The diagnosis of pregnancy will be confirmed by the detection of positive serum beta-hCG (human chorionic gonadotropin) levels and ultrasound confirmation of intrauterine gestation. Trimesters will be clearly classified according to gestational week determined by ultrasound. The included participants will be followed in the 1st (weeks 0-13), 2nd (weeks 14-27), and 3rd trimesters (week 28 and later), as well as at 6-8 weeks postpartum.
The control group will consist of 15 systemically healthy volunteers aged 18-40, who apply to the Department of Periodontology at Bezmialem Vakıf University. These participants will have a regular menstrual cycle, no hormonal disorders or systemic diseases, and no pregnancy within the last six months. Informed consent will be obtained from all participants before enrollment. Medical and dental histories will be recorded at the beginning of the study.
To evaluate periodontal status, plaque index (PI), bleeding on probing (BOP), probing depth (PD in mm), and clinical attachment level (CAL) will be measured at each visit (1st, 2nd, and 3rd trimesters and postpartum period for pregnant women, and early follicular phase of spontaneous or progesterone-induced menstrual cycle for controls). All measurements will be performed by a single calibrated periodontist at the Department of Periodontology, Bezmialem Vakıf University. Periodontal parameters will be recorded at six sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, and distolingual) using a Williams periodontal probe (Hu-Friedy, Chicago, IL). Third molars will be excluded.
Participants with no clinical attachment loss, probing depth ≤3 mm, and bleeding on probing <10% will be classified as periodontally healthy. Those with no clinical attachment loss, probing depth ≤3 mm, and BOP >30% will be considered as having gingivitis. Participants with interproximal clinical attachment loss on at least two non-adjacent teeth and probing depth ≥4 mm will be diagnosed with periodontitis. Oral hygiene instructions will include the use of mechanical aids only (toothbrush, dental floss, interdental brush), and participants will be instructed to avoid using mouthwash or antimicrobial agents.
Before clinical periodontal measurements, saliva samples will be collected by another periodontist. Participants will be instructed not to eat or drink anything (except water) and not to chew gum before sampling, following an overnight fast. Unstimulated saliva will be collected by asking the participant to pool saliva in the mouth for approximately 5 minutes and then gently spit approximately 2.0 mL of saliva into a sterile glass beaker. The samples will then be transferred to sterile Eppendorf tubes using a micropipette, labeled, and stored at -80°C until analysis.
Before analysis, all saliva samples will be centrifuged at +4°C, 10,000 g for 10 minutes by a single researcher at the Department of Medical Biochemistry, Bezmialem Vakıf University, to remove particulate matter. The samples will then be prepared for LC-MS/MS analysis. In the LC-MS/MS system, each sample will first be separated into components by liquid chromatography (LC) and then identified based on their molecular masses using mass spectrometry (MS).
The data obtained from mass spectrometry will be analyzed using metabolite identification software and international metabolite databases (HMDB, KEGG, METLIN, etc.). The resulting metabolomic profiles will be used to explore biological pathways associated with pregnancy and periodontal status.
- Conditions
- Pregnancy, Gingivitis and Periodontal Diseases
- Keywords
- pregnancy, gingivitis, periodontal disease, saliva, metabolomics, LC-MS/MS
- Medical subject headings
- Gingivitis, Periodontal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Pregnant Women | This group includes 15 healthy pregnant women aged 18-40 with uncomplicated pregnancies. Saliva samples are collected at four time points: during the first (0-13 weeks), second (14-27 weeks), and third trimesters (28 weeks and later), and at 6-8 weeks postpartum. No medical intervention is applied. The aim is to analyze changes in periodontal parameters and salivary metabolite profiles over time using untargeted metabolomics via LC-MS/MS. | |
| Non-Pregnant Healthy Controls | This group includes 15 systemically healthy, non-pregnant women aged 18-40 with regular menstrual cycles and no history of pregnancy in the past 6 months. Saliva and periodontal measurements are collected during the early follicular phase of the menstrual cycle. These participants serve as the control group for comparative evaluation of salivary metabolomic profiles and periodontal health status. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Salivary Metabolite Profile by Pregnancy Status
Untargeted metabolomic analysis of saliva samples will be performed using LC-MS/MS to identify metabolite patterns associated with different stages of pregnancy and periodontal status. Results will be reported as relative metabolite concentrations (normalized intensity, arbitrary units).
Measured: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Secondary outcomes (3)
Bleeding on Probing (BOP)
Bleeding will be recorded at six sites per tooth using gentle probing. The outcome will be reported as the percentage of bleeding sites per participant.
Measured: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Plaque Index score
Plaque accumulation will be assessed using the Silness-Löe Plaque Index (range: 0-3). The mean plaque index score per participant will be reported.
Measured: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Mean probing depth (PD)
Probing depth will be measured in millimeters (mm) at six sites per tooth. The average probing depth per participant will be reported.
Measured: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2025
- Study start24 Jun 2025
- Primary completionMar 2026 (estimated)
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PregnancyStudies of the same condition, open and under way.
- More trials run by Bezmialem Vakif UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
- Target duration
- 9 Months
Sponsor and investigators
- Lead sponsor
- Bezmialem Vakif University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07054177
- Sponsor's protocol ID
- E195935
- Status last verified
- Jul 2025
- First submitted
- 25 Jun 2025
- Last updated
- 23 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Salivary Metabolomics of Pregnancy and Periodontal Disease Related Metabolic Pathways
- ClinicalTrials.gov ID
- NCT07054177
- Acronym / sponsor ID
- E195935
- Conditions
- Pregnancy, Gingivitis and Periodontal Diseases
- Keywords
- pregnancy, gingivitis, periodontal disease, saliva, metabolomics, LC-MS/MS
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Bezmialem Vakif UniversityUniversity, hospital or other
- Study start
- 24 Jun 2025 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Apr 2026 (estimated)
- First posted
- 8 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to better understand how pregnancy affects the health of the gums and tissues that support the teeth. During pregnancy, hormone levels (like estrogen and progesterone) increase significantly. These hormonal changes can cause many changes in the body, including in the mouth. Some pregnant women may notice that their gums become swollen, red, or bleed more easily - this is called pregnancy gingivitis. It happens more often during the second and third trimesters and usually improves after birth. Even if a pregnant person has good oral hygiene, hormonal changes may still make the gums more sensitive to plaque and bacteria. Scientists believe that these changes in gum health are linked to how the body responds to hormones, bacteria in the mouth, and changes in the immune system. To explore this further, saliva samples will be collected from:
- Pregnant women during their 1st, 2nd, and 3rd trimesters
- The same women again 6-8 weeks after giving birth
- A group of non-pregnant, healthy women as a comparison group The investigators will use a scientific method called untargeted metabolomics to study these saliva samples. This method helps looking at small substances (called metabolites) in saliva to see if there are any patterns related to pregnancy and gum health.
The goal is to identify biological changes that happen during pregnancy and understand how they might affect the gums. This research will help improve early detection and prevention of gum problems during pregnancy in the future.
Detailed description
The main objective of this study is to investigate the impact of physiological hormonal changes during pregnancy on periodontal status and to determine the metabolic pathways through which this effect occurs. For this purpose, saliva samples collected at different stages of pregnancy (1st, 2nd, and 3rd trimesters), in the postpartum period, and from systemically healthy non-pregnant individuals will be analyzed using an untargeted metabolomic approach based on LC-MS/MS. The analysis aims to identify potential metabolites and biochemical pathways that reflect the relationship between pregnancy-associated hormonal changes and periodontal tissues, thereby contributing to a better understanding of the underlying biological mechanisms.
This study will include 15 volunteer pregnant women aged 18-40, who are systemically healthy and whose pregnancy is progressing without complications, followed by a single gynecologist at the Department of Obstetrics and Gynecology, Bezmialem Vakıf University. The diagnosis of pregnancy will be confirmed by the detection of positive serum beta-hCG (human chorionic gonadotropin) levels and ultrasound confirmation of intrauterine gestation. Trimesters will be clearly classified according to gestational week determined by ultrasound. The included participants will be followed in the 1st (weeks 0-13), 2nd (weeks 14-27), and 3rd trimesters (week 28 and later), as well as at 6-8 weeks postpartum.
The control group will consist of 15 systemically healthy volunteers aged 18-40, who apply to the Department of Periodontology at Bezmialem Vakıf University. These participants will have a regular menstrual cycle, no hormonal disorders or systemic diseases, and no pregnancy within the last six months. Informed consent will be obtained from all participants before enrollment. Medical and dental histories will be recorded at the beginning of the study.
To evaluate periodontal status, plaque index (PI), bleeding on probing (BOP), probing depth (PD in mm), and clinical attachment level (CAL) will be measured at each visit (1st, 2nd, and 3rd trimesters and postpartum period for pregnant women, and early follicular phase of spontaneous or progesterone-induced menstrual cycle for controls). All measurements will be performed by a single calibrated periodontist at the Department of Periodontology, Bezmialem Vakıf University. Periodontal parameters will be recorded at six sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, and distolingual) using a Williams periodontal probe (Hu-Friedy, Chicago, IL). Third molars will be excluded.
Participants with no clinical attachment loss, probing depth ≤3 mm, and bleeding on probing <10% will be classified as periodontally healthy. Those with no clinical attachment loss, probing depth ≤3 mm, and BOP >30% will be considered as having gingivitis. Participants with interproximal clinical attachment loss on at least two non-adjacent teeth and probing depth ≥4 mm will be diagnosed with periodontitis. Oral hygiene instructions will include the use of mechanical aids only (toothbrush, dental floss, interdental brush), and participants will be instructed to avoid using mouthwash or antimicrobial agents.
Before clinical periodontal measurements, saliva samples will be collected by another periodontist. Participants will be instructed not to eat or drink anything (except water) and not to chew gum before sampling, following an overnight fast. Unstimulated saliva will be collected by asking the participant to pool saliva in the mouth for approximately 5 minutes and then gently spit approximately 2.0 mL of saliva into a sterile glass beaker. The samples will then be transferred to sterile Eppendorf tubes using a micropipette, labeled, and stored at -80°C until analysis.
Before analysis, all saliva samples will be centrifuged at +4°C, 10,000 g for 10 minutes by a single researcher at the Department of Medical Biochemistry, Bezmialem Vakıf University, to remove particulate matter. The samples will then be prepared for LC-MS/MS analysis. In the LC-MS/MS system, each sample will first be separated into components by liquid chromatography (LC) and then identified based on their molecular masses using mass spectrometry (MS).
The data obtained from mass spectrometry will be analyzed using metabolite identification software and international metabolite databases (HMDB, KEGG, METLIN, etc.). The resulting metabolomic profiles will be used to explore biological pathways associated with pregnancy and periodontal status.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 9 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pregnant Women | – | –This group includes 15 healthy pregnant women aged 18-40 with uncomplicated pregnancies. Saliva samples are collected at four time points: during the first (0-13 weeks), second (14-27 weeks), and third trimesters (28 weeks and later), and at 6-8 weeks postpartum. No medical intervention is applied. The aim is to analyze changes in periodontal parameters and salivary metabolite profiles over time using untargeted metabolomics via LC-MS/MS. |
| Non-Pregnant Healthy Controls | – | –This group includes 15 systemically healthy, non-pregnant women aged 18-40 with regular menstrual cycles and no history of pregnancy in the past 6 months. Saliva and periodontal measurements are collected during the early follicular phase of the menstrual cycle. These participants serve as the control group for comparative evaluation of salivary metabolomic profiles and periodontal health status. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- The study population includes systemically healthy pregnant women in different trimesters and postpartum period, and non-pregnant healthy women aged 18-40 years attending routine gynecology or periodontology clinics.
Key inclusion criteria (13 listed)
- Age between 18 and 40 years
- No history of systemic disease or chronic infection
- No use of antibiotics or anti-inflammatory drugs in the last 3 months
- Non-smoker and non-alcohol user
- Willingness to participate by signing the informed consent form
Key exclusion criteria (8 listed)
- Use of anti-inflammatory or antimicrobial treatments in the past 3 months
- Smoking or alcohol consumption
- Body mass index (BMI) > 30 kg/m²
- Presence of systemic diseases including diabetes mellitus, hyperprolactinemia, congenital adrenal hyperplasia, androgen-secreting tumors, thyroid dysfunction, Cushing's syndrome, hypertension, liver or kidney dysfunction
- Use of medications that may affect metabolic or hormonal parameters, such as oral contraceptives, steroid hormones, antihypertensives, or insulin-sensitizing drugs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Salivary Metabolite Profile by Pregnancy Status
Time frame: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Untargeted metabolomic analysis of saliva samples will be performed using LC-MS/MS to identify metabolite patterns associated with different stages of pregnancy and periodontal status. Results will be reported as relative metabolite concentrations (normalized intensity, arbitrary units).
3 secondary outcomes
Bleeding on Probing (BOP)
Time frame: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Plaque Index score
Time frame: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Mean probing depth (PD)
Time frame: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pregnancy and Gingivitis and Periodontal Diseases, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cansu Can Yasar, Periodontist (+905453153495, cansu.ysr@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Salivary Metabolite Profile by Pregnancy Status (time frame: Baseline, 1st trimester (0-13 weeks), 2nd trimester (14-27 weeks), 3rd trimester (28 weeks and later), and 6-8 weeks postpartum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2025.